IPSEN (OTCMKTS:IPSEY) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why

IPSEN (OTCMKTS:IPSEY)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $37.32 and traded as high as $45.44. IPSEN shares last traded at $45.28, with a volume of 2,134 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IPSEY. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research note on Tuesday, February 17th. BNP Paribas Exane lowered IPSEN to an “underperform” rating in a report on Wednesday, November 26th. Finally, UBS Group cut IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold”.

IPSEN Trading Down 3.1%

The company’s fifty day moving average price is $42.07 and its 200 day moving average price is $37.45.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).